Defects in Mitochondrial Dynamics and Metabolomic Signatures of Evolving Energetic Stress in Mouse Models of Familial Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The identification of early mechanisms underlying Alzheimer's Disease (AD) and associated biomarkers could advance development of new therapies and improve monitoring and predicting of AD progression. Mitochondrial dysfunction has been suggested to underlie AD pathophysiology, however, no comprehensive study exists that evaluates the effect of different familial AD (FAD) mutations on mitochondrial function, dynamics, and brain energetics. METHODS AND FINDINGS: We characterized early mitochondrial dysfunction and metabolomic signatures of energetic stress in three commonly used transgenic mouse models of FAD. Assessment of mitochondrial motility, distribution, dynamics, morphology, and metabolomic profiling revealed the specific effect of each FAD mutation on the development of mitochondrial stress and dysfunction. Inhibition of mitochondrial trafficking was characteristic for embryonic neurons from mice expressing mutant human presenilin 1, PS1(M146L) and the double mutation of human amyloid precursor protein APP(Tg2576) and PS1(M146L) contributing to the increased susceptibility of neurons to excitotoxic cell death. Significant changes in mitochondrial morphology were detected in APP and APP/PS1 mice. All three FAD models demonstrated a loss of the integrity of synaptic mitochondria and energy production. Metabolomic profiling revealed mutation-specific changes in the levels of metabolites reflecting altered energy metabolism and mitochondrial dysfunction in brains of FAD mice. Metabolic biomarkers adequately reflected gender differences similar to that reported for AD patients and correlated well with the biomarkers currently used for diagnosis in humans. CONCLUSIONS: Mutation-specific alterations in mitochondrial dynamics, morphology and function in FAD mice occurred prior to the onset of memory and neurological phenotype and before the formation of amyloid deposits. Metabolomic signatures of mitochondrial stress and altered energy metabolism indicated alterations in nucleotide, Krebs cycle, energy transfer, carbohydrate, neurotransmitter, and amino acid metabolic pathways. Mitochondrial dysfunction, therefore, is an underlying event in AD progression, and FAD mouse models provide valuable tools to study early molecular mechanisms implicated in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Kind, T., Wohlgemuth, G., Lee, D. Y., Lu, Y., Palazoglu, M., Shahbaz, S., & Fiehn, O. (2009) · Analytical Chemistry · doi:10.1021/ac9019522 · Cited by 1,482
Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.-M., Perez-tur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D., et al. (1996) · Nature · doi:10.1038/383710a0 · Cited by 1,465
Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases
Chen, H., & Chan, D. C. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp326 · Cited by 1,458
Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
Mitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367 · cited 1×
“Recently, defects in mitochondrial morphology, distribution and dynamics have been found in the human AD brain tissue and in cellular and animal models of AD [20,22,36,44–46].”
BackgroundDong, X.-X., Wang, Y., & Qin, Z.-H. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.24 · Cited by 1,297
Kalaria, R. N., Maestre, G. E., Arizaga, R., Friedland, R. P., Galasko, D., Hall, K., Luchsinger, J. A., Ogunniyi, A., Perry, E. K., Potocnik, F., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70169-8 · Cited by 1,233
Cited by
Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease
Tönnies, E., & Trushina, E. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161088 · Cited by 1,750
“Application of Systems Biology approaches including metabolomics and epigenetics to study early changes associated with AD progression in plasma, CSF, and brain tissue from individuals with different severity of AD and multiple animal models of AD confirmed that major alterations in metabolic networks identified early…”
MethodSelf-citationOxidative stress and mitochondrial dysfunction in Alzheimer’s disease
Wang, X., Wang, W., Li, L., Perry, G., Lee, H.-G., & Zhu, X. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.10.015 · Cited by 1,357
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: Recent advances.
Wang, W., Zhao, F., Ma, X., Perry, G., & Zhu, X. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00376-6 · Cited by 1,274
Mitochondrial Defects and Oxidative Stress in Alzheimer Disease and Parkinson Disease
Yan, M. H., Wang, X., & Zhu, X. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.11.014 · Cited by 718
“However, no changes in the expression of any fission/fusion proteins are identified in the brain tissue of these mice [98].”
BackgroundMitochondrial dynamics in neurodegeneration
Itoh, K., Nakamura, K., Iijima, M., & Sesaki, H. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2012.10.006 · Cited by 464
Self-citationTrushina, E., Dutta, T., Persson, X.-M. T., Mielke, M. M., & Petersen, R. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063644 · Cited by 438
“We have previously demonstrated the presence of metabolic signatures of energetic stress and mitochondrial dysfunction in brain tissue from three transgenic mouse models of familial AD (FAD) [25].”
BackgroundInfluentialSelf-citationMitochondria: A central target for sex differences in pathologies
Ventura-Clapier, R., Moulin, M., Piquereau, J., Lemaire, C., Mericskay, M., Veksler, V., & Garnier, A. (2017) · Clinical Science · doi:10.1042/cs20160485 · Cited by 371
Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice
Yue, M., Hinkle, K. M., Davies, P., Trushina, E., Fiesel, F. C., Christenson, T. A., Schroeder, A. S., Zhang, L., Bowles, E., Behrouz, B., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.02.031 · Cited by 281
Self-citationParkin-mediated mitophagy in mutant hAPP neurons and Alzheimer's disease patient brains
Ye, X., Sun, X., Starovoytov, V., & Cai, Q. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv056 · Cited by 274
“Abnormal mitochondria were defined as having swollen round shape, and reduced, disorganized or loss of internal cristae (18).”
BackgroundBACE1 inhibitors: Current status and future directions in treating Alzheimer's disease
Moussa‐Pacha, N. M., Abdin, S. M., Omar, H. A., Alniss, H., & Al‐Tel, T. H. (2020) · Medicinal Research Reviews · doi:10.1002/med.21622 · Cited by 274
Mitochondrial Aspects of Synaptic Dysfunction in Alzheimer’s Disease
Cai, Q., & Tammineni, P. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160726 · Cited by 272
Application of Metabolomics in Alzheimer’s Disease
Wilkins, J. M., & Trushina, E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2017.00719 · Cited by 268
Self-citationEnergy matters: presynaptic metabolism and the maintenance of synaptic transmission
Li, S., & Sheng, Z.-H. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00535-8 · Cited by 267
Quantitative 3D Mapping of the Human Skeletal Muscle Mitochondrial Network
Vincent, A. E., White, K., Davey, T., Philips, J., Ogden, R. T., Lawless, C., Warren, C., Hall, M. G., Ng, Y. S., Falkous, G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.010 · Cited by 195
Amyloid-β Peptides are Generated in Mitochondria-Associated Endoplasmic Reticulum Membranes
Schreiner, B., Hedskog, L., Wiehager, B., & Ankarcrona, M. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132543 · Cited by 192
Inhibition of mitochondrial fragmentation protects against Alzheimer’s disease in rodent model
Wang, W., Yin, J., Ma, X., Zhao, F., Siedlak, S. L., Wang, Z., Torres, S., Fujioka, H., Xu, Y., Perry, G., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx299 · Cited by 175
“Abnormal mitochondrial distribution and round, swollen and damaged mitochondria are also documented in Alzheimer’s disease mouse models (22,23) although it remains to be determined whether mitochondria actually fragment or elongate in vivo”
The role of mitophagy in the regulation of mitochondrial energetic status in neurons
Han, S., Zhang, M., Jeong, Y. Y., Margolis, D. J., & Cai, Q. (2021) · Autophagy · doi:10.1080/15548627.2021.1907167 · Cited by 151
Birnbaum, J. H., Wanner, D., Gietl, A. F., Saake, A., Kündig, T. M., Hock, C., Nitsch, R. M., & Tackenberg, C. (2018) · Stem Cell Research · doi:10.1016/j.scr.2018.01.019 · Cited by 135
Corsetti, V., Florenzano, F., Atlante, A., Bobba, A., Ciotti, M. T., Natale, F., Della Valle, F., Borreca, A., Manca, A., Meli, G., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv059 · Cited by 129
Reddy, P. H., Manczak, M., & Yin, X. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170051 · Cited by 116
Glutamatergic synaptic plasticity and dysfunction in Alzheimer disease: Emerging mechanisms
Benarroch, E. E. (2018) · Neurology · doi:10.1212/wnl.0000000000005807 · Cited by 115
Aerobic glycolysis in the primate brain: Reconsidering the implications for growth and maintenance
Bauernfeind, A. L., Barks, S. K., Duka, T., Grossman, L. I., Hof, P. R., & Sherwood, C. C. (2014) · Brain Structure and Function · doi:10.1007/s00429-013-0662-z · Cited by 105
“This evidence suggests that regions of the neocortex that are susceptible to AD pathology are characterized by increased aerobic glycolysis and decreased oxidative phosphorylation, and indeed, these characteristics are evident prior to other neuropathologic changes in AD (Chandrasekaran et al. 1994; Fukuyama et al. 19…”
BackgroundMartins, N. R. B., Angelica, A., Chakravarthy, K., Svidinenko, Y., Boehm, F. J., Opris, I., Lebedev, M. A., Swan, M., Garan, S. A., Rosenfeld, J. V., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00112 · Cited by 91
Kodam, P., Sai Swaroop, R., Pradhan, S. S., Sivaramakrishnan, V., & Vadrevu, R. (2023) · Scientific Reports · doi:10.1038/s41598-023-30892-6 · Cited by 82
Caspase-Cleaved Tau Impairs Mitochondrial Dynamics in Alzheimer’s Disease
Pérez, M. J., Vergara-Pulgar, K., Jara, C., Cabezas-Opazo, F., & Quintanilla, R. A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0385-x · Cited by 81
Stojakovic, A., Trushin, S., Sheu, A., Khalili, L., Chang, S.-Y., Li, X., Christensen, T., Salisbury, J. L., Geroux, R. E., Gateno, B., et al. (2021) · Communications Biology · doi:10.1038/s42003-020-01584-y · Cited by 72
Self-citationAn Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?
Sciaccaluga, M., Megaro, A., Bellomo, G., Ruffolo, G., Romoli, M., Palma, E., & Costa, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115991 · Cited by 70
“Interestingly, Aβ oligomers also interfere with mitochondrial bidirectional axonal trafficking [102,103].”
BackgroundGray, N. E., Zweig, J. A., Matthews, D. G., Caruso, M., Quinn, J. F., & Soumyanath, A. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/7023091 · Cited by 60
González-Domínguez, R., García-Barrera, T., Vitorica, J., & Gómez-Ariza, J. L. (2015) · Biochimie · doi:10.1016/j.biochi.2015.01.005 · Cited by 49
Mitochondrial Genome Analysis of Primary Open Angle Glaucoma Patients
Banerjee, D., Banerjee, A., Mookherjee, S., Vishal, M., Mukhopadhyay, A., Sen, A., Basu, A., & Ray, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070760 · Cited by 48
“A transgenic mouse model bearing a familial Alzheimer’s disease mutation showed mutation-specific alterations in mitochondrial dynamics, morphology and function that preceded the onset of memory and neurological phenotype and the formation of amyloid plaques [24].”
Hurtado, M. O., Kohler, I., & de Lange, E. C. M. (2018) · Bioanalysis · doi:10.4155/bio-2018-0135 · Cited by 34
Montesanto, A., Crocco, P., Anfossi, M., Smirne, N., Puccio, G., Colao, R., Maletta, R., Passarino, G., Bruni, A. C., & Rose, G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150993 · Cited by 24
Mitochondrial vulnerability to oxidation in human brain organoids modelling Alzheimer's disease
Holubiec, M. I., Alloatti, M., Bianchelli, J., Greloni, F., Arnaiz, C., Gonzalez Prinz, M., Fernandez Bessone, I., Pozo Devoto, V., & Falzone, T. L. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.08.028 · Cited by 20
Human Connectome Mapping and Monitoring Using Neuronanorobots
Martins, N. R. B., Erlhagen, W., & Freitas, Jr. (2016) · Journal of Ethics and Emerging Technologies · doi:10.55613/jeet.v26i1.49 · Cited by 3
Metadata
- Authors
- Trushina, E., Nemutlu, E., Zhang, S., Christensen, T., Camp, J., Mesa, J., Siddiqui, A., Tamura, Y., Sesaki, H., Wengenack, T. M., Dzeja, P. P., & Poduslo, J. F.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-02-29
- Volume
- 7
- Issue
- 2
- Pages
- e32737
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2026308971
- Cited by
- 266
- References
- 83
- FWCI
- 14.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.